These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 30706803)

  • 1. Current and Future Pharmacologic Therapies for Diabetic Retinopathy.
    Villegas VM; Schwartz SG
    Curr Pharm Des; 2018; 24(41):4903-4910. PubMed ID: 30706803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of aflibercept and conbercept in diabetic macular edema.
    Cai S; Yang Q; Li X; Zhang Y
    Drug Des Devel Ther; 2018; 12():3471-3483. PubMed ID: 30410308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
    Emerson MV; Lauer AK
    BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on current pharmacologic therapies for diabetic retinopathy.
    Muns SM; Villegas VM; Flynn HW; Schwartz SG
    Expert Opin Pharmacother; 2023; 24(14):1577-1593. PubMed ID: 37431888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current intravitreal pharmacologic therapies for diabetic macular edema.
    Colucciello M
    Postgrad Med; 2015 Aug; 127(6):640-53. PubMed ID: 26036708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drugs for diabetic macular edema.
    Schwartz SG; Flynn HW; Scott IU
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):397-405. PubMed ID: 25141904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab in the Treatment of Diabetic Macular Edema: A Review of the Current Status, Unmet Needs, and Emerging Challenges.
    Dervenis N; Mikropoulou AM; Tranos P; Dervenis P
    Adv Ther; 2017 Jun; 34(6):1270-1282. PubMed ID: 28484955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corticosteroid use for diabetic macular edema: old fad or new trend?
    Stewart MW
    Curr Diab Rep; 2012 Aug; 12(4):364-75. PubMed ID: 22581206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema.
    Yonekawa Y; Modi YS; Kim LA; Skondra D; Kim JE; Wykoff CC
    J Vitreoretin Dis; 2020 Mar; 4(2):125-135. PubMed ID: 34308094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy.
    Berrocal MH; Acaba LA; Chenworth ML
    Curr Diab Rep; 2019 Sep; 19(10):106. PubMed ID: 31529405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical Lessons from Protocol I for the Management of Diabetic Macular Edema.
    Mukkamala L; Bhagat N; Zarbin MA
    Dev Ophthalmol; 2017; 60():91-108. PubMed ID: 28427069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?
    Li X; Zarbin MA; Bhagat N
    Dev Ophthalmol; 2017; 60():131-142. PubMed ID: 28427072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VEGF-A gene polymorphisms and responses to intravitreal ranibizumab treatment in patients with diabetic macular edema.
    Tetikoğlu M; Yüksel Z; Aktas S; Sağdik HM; Özcura F
    Int Ophthalmol; 2018 Dec; 38(6):2381-2388. PubMed ID: 29030794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab and Panretinal photocoagulation protect against ocular hypertension after posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.
    Hsieh YT; Yang CM; Chang SH
    J Formos Med Assoc; 2017 Aug; 116(8):599-605. PubMed ID: 28277285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
    Wykoff CC; Ou WC; Khurana RN; Brown DM; Lloyd Clark W; Boyer DS;
    Br J Ophthalmol; 2018 May; 102(5):631-636. PubMed ID: 28814412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.
    Hussain RM; Ciulla TA
    Expert Opin Biol Ther; 2016; 16(3):365-74. PubMed ID: 26674182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluocinolone acetonide implantable device for diabetic retinopathy.
    Schwartz SG; Flynn HW
    Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.